Video Library

Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University discusses Liquid Biopsies for EGFR.

Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University discusses the Role for Immunotherapy for Patients with Driver Mutations.

Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University discusses Multiple Immunotherapy Agents.

Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University discusses First Line Immunotherapy for Advanced Non-Small Cell Lung Cancer NSCLC.

Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, & Clinical Associate Prof. of Medicine at FL International University joined GRACE to discuss the response time on checkpoint inhibitors and the concept of pseudoprogression.

Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International U. joined GRACE to discuss biomarkers for predicting activity of immune checkpoint inhibitors.

Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International U. joined GRACE to discuss potential side effects of immune checkpoint inhibitors and basic management approaches.

Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International U. joined GRACE to discuss integrating immune checkpoint inhibitors into first-line therapy for advanced NSCLC.

Dr. Luis Raez, MD FACP FCCP, Chief of Hematology/Oncology and Medical Director at Memorial Cancer Institute, and Clinical Associate Professor of Medicine at Florida International University joined GRACE to discuss second-line therapies for advanced NSCLC.

Dr. Luis Raez, MD FACP FCCP, Chief of Hematology/Oncology and Med. Director at Memorial Cancer Institute, and Clinical Associate Professor of Medicine at FL International University joined GRACE to discuss immune checkpoint inhibitors and how they can treat cancer.

For our 16th video in the GRACE Spanish Lung Cancer Library, Brian Hunis, MD joined GRACE to discuss ALK rearrangements, what they are who has them.

For our 9th video in the GRACE Spanish Lung Cancer Library, Brian Hunis, MD joined GRACE to discuss the pros and cons of lung cancer screening.

Dr. Jed Gorden, Swedish Cancer Institute, describes the differences between bronchoscopy and endobronchial ultrasound, highlighting the advantages of EBUS in diagnosis and staging.

Dr. Jack West, Swedish Cancer Institute, compares the mechanism of action, efficacy and toxicity of PD-1 and PD-L1 inhibitors.

Dr. Ross Camidge, University of Colorado, describes ROS-1 rearrangements and compares them to ALK rearrangements in frequency of occurrence and response to treatment.